Do Arthritis Drugs Lower Parkinson’s Risk? What 26 Studies Actually Found

Key points

• Anti-inflammatory and immune-modifying drugs have been linked to a lower rate of Parkinson's disease, but the link is not equally strong across every drug class.
• In a meta-analysis of 26 studies covering more than 4.3 million people, ordinary anti-inflammatory painkillers showed no protective effect at all. Corticosteroids and disease-modifying antirheumatic drugs (DMARDs) did.
• "Twenty per cent lower risk" sounds enormous and usually isn't. When a condition is uncommon to begin with, a large-sounding percentage can mean a very small change in real terms.
• None of this evidence comes from randomised trials, so it cannot yet tell us whether the drugs are doing the protecting.
• Nobody should start, stop, or change a prescription on the strength of findings like these.

Every so often a study surfaces suggesting that a drug millions of people already take might quietly protect them from something far worse. The headline writes itself: the arthritis pill that may prevent Parkinson's.

If you live with rheumatoid arthritis, or you care for someone with Parkinson's, that headline is not an abstraction. It is a reason to phone your rheumatologist, or a reason to feel you have been missing out on something.

I was part of the team that pooled this evidence together, and the honest answer is more interesting than the headline. It is also considerably more restrained.

Why researchers linked arthritis drugs to Parkinson's in the first place

The idea did not come from nowhere.

Parkinson's disease develops as dopamine-producing cells in a small region of the brain gradually die off. For decades, researchers have suspected that inflammation is part of what drives that process. Post-mortem brain tissue from people with Parkinson's shows activated immune cells clustered around the damage. Laboratory work suggests that dampening that immune response can slow the loss of neurons.

Rheumatoid arthritis, meanwhile, is a condition defined by chronic inflammation. The people who have it spend years, sometimes decades, taking drugs designed to switch that inflammation off.

So there was a reasonable question sitting there: if inflammation contributes to Parkinson's, do people on long-term anti-inflammatory treatment develop it less often?

Individual studies had gone looking, and they disagreed with each other. Some found protection. Some found nothing. A few pointed the other way. That disagreement is exactly the situation a meta-analysis exists to resolve.

How we reviewed 26 studies covering 4.3 million people

We searched three major research databases and pulled together every study we could find that measured Parkinson's risk in people taking four categories of drug: non-steroidal anti-inflammatory drugs (NSAIDs, the ibuprofen and aspirin family), paracetamol, corticosteroids, and DMARDs such as methotrexate and hydroxychloroquine.

Twenty-six studies met the criteria. Together they covered 4,321,104 people, among whom 150,703 had Parkinson's disease.

Then we pooled the results by drug class rather than lumping everything together. That turned out to matter a great deal.

Do ibuprofen and aspirin lower Parkinson's risk?

Ordinary anti-inflammatory painkillers showed nothing. Across 18 studies, the pooled relative risk for NSAIDs was 0.96, with a confidence interval running from 0.83 to 1.11.

That interval is the important part. It spans 1.0, the point at which there is no difference at all. In plain terms: once you combine all the evidence, the data are equally compatible with a small protective effect, a small harmful effect, and nothing whatsoever. This is the result that would have made the best headline, and it is the result that dissolved.

What corticosteroids and DMARDs showed

Corticosteroids showed a consistent reduction. Pooled relative risk of 0.80, with a tight interval of 0.77 to 0.84. Dexamethasone specifically came out at 0.69.

DMARDs showed the largest reduction. Pooled relative risk of 0.69, interval 0.55 to 0.86, with hydroxychloroquine at 0.77.

A relative risk of 0.80 means people taking corticosteroids developed Parkinson's roughly 20% less often than people who were not.

What does a "20% lower risk" of Parkinson's actually mean?

This is where reporting of this kind of research quietly misleads people, and it is worth slowing down.

A 20% reduction sounds like a fifth of a large problem removed. But relative risk describes a proportion of a baseline, and it tells you nothing at all about how big that baseline was.

Parkinson's disease is uncommon. Roughly one person in a hundred over the age of 60 will develop it. Cutting that risk by a fifth does not take you from a high risk to a low one. It moves you from a small number to a slightly smaller number.

The percentage is real. It is also, for any individual person, a modest thing. Both of those statements are true at once, and a reader deserves to be handed both rather than whichever one makes for better copy.

Why this doesn't prove arthritis drugs prevent Parkinson's

Every study we pooled was observational. We watched what happened to people who happened to be taking these medicines. Nobody was randomly assigned to treatment, which means the groups being compared differ in ways beyond the drug.

Three of those differences matter enough to name.

Confounding by indication. People prescribed long-term corticosteroids or DMARDs have an underlying condition. That condition, its severity, and everything else about their health may influence Parkinson's risk independently of the medication.

Reverse causation. Parkinson's begins years, possibly decades, before the tremor that leads to a diagnosis. During that silent phase, people move less, sleep differently, and experience pain differently. It is entirely plausible that early, undiagnosed Parkinson's changes which painkillers someone reaches for, rather than the painkillers changing the Parkinson's.

Detection differences. Someone on a DMARD sees a specialist regularly and has their bloods monitored. That is a different relationship with the health system than the general population has, and different levels of medical contact produce different rates of diagnosis.

None of this makes the finding worthless. It makes it a signal worth testing properly, which is a genuinely different claim from these drugs prevent Parkinson's. Only a randomised controlled trial can close that gap, by assigning the drug deliberately and following people for years.

Worried about your own Parkinson's risk? What to do next

Health risk information can be destabilising, particularly if you live with a long-term condition and have already spent years managing uncertainty about your own body.

A few things worth holding onto.

A population finding is not a prediction about you. Meta-analyses describe averages across millions of people. They cannot tell any individual what will happen.

Nothing here justifies changing a prescription. Corticosteroids and DMARDs carry real risks, which is why they are prescribed carefully and monitored closely. No one should seek them out on the basis of an observational signal, and no one should stop a medicine that is working.

Bring the question to the person who knows your history. If a headline has unsettled you, that is a legitimate thing to raise at your next appointment. It is a reasonable question, not a silly one.

The final word on arthritis drugs and Parkinson's disease

The finding is genuine: in pooled data from more than four million people, corticosteroid and DMARD use was associated with a lower rate of Parkinson's disease, while common anti-inflammatory painkillers were not.

What that earns is a properly designed trial. What it does not earn is a change to anyone's medication, or the impression that a preventive treatment for Parkinson's is already sitting in the medicine cabinet.

Good health writing has to hold both of those at once. Most of the harm done by health content online comes not from inventing findings, but from stripping away the conditions under which a real finding is true.

Based on: Mady A, Kashbour M, Abu-Qare'e O, Jaffal R, Khaled A, et al. Rheumatoid arthritis drugs and the risk of Parkinson's disease – a meta-analysis. NeuroImmune Pharmacology and Therapeutics. 2025;4(1):13–26. doi:10.1515/nipt-2024-0023